MTHFR C677T polymorphisms are associated with aberrant methylation of the IGF-2 gene in transitional cell carcinoma of the bladder

Journal of Biomedical Research

Volumn 26, Issue 2, 2012, Pages 77-83

  Cheng, Huan ^a   Deng, Zhonglei ^a   Wang, Zengjun ^a   Zhang, Wei ^a   Su, Jiantang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bladder transitional cell carcinoma; Epidemiology; Folate; Insulin like growth factor 2 (IGF 2); Methylation; Methylenetetrahydrofolate reductase

Indexed keywords

METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); SOMATOMEDIN B;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLADDER CANCER; BLADDER TRANSITIONAL CELL CARCINOMA; CPG ISLAND; DNA METHYLATION; FEMALE; GENETIC POLYMORPHISM; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; TEA;

EID: 84859702853     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1674-8301(12)60015-3     Document Type: Article

References (36)

1. Marsit CJ, Houseman EA, Christensen BC, Gagne L, Wrensch MR, Nelson HH, et al. Identification of meth-ylated genes associated with aggressive bladder cancer. PLoS One 2010, 5:e12334.
2. Vikram R, Sandler CM, Ng CS Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract. AJR Am J Roentgenol 2009, 192:1481-1487.
3. Hansen MF, Cavenee WK Tumor suppressors: recessive mutations that lead to cancer. Cell 1988, 53:173-174.
4. Hunter T Oncoprotein networks. Cell 1997, 88:333-346.
5. Jones PA, Baylin SB The epigenomics of cancer. Cell 2007, 128:683-692.
6. Fang JY, Lu R, Mikovits JA, Cheng ZH, Zhu HY, Chen YX Regulation of hMSH2 and hMLH1 expression in the human colon cancer cell line SW1116 by DNA methyltransferase 1. Cancer Lett 2006, 233:124-130.
7. Tada Y, Yokomizo A, Shiota M, Tsunoda T, Plass C, Naito S Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer. Int J Oncol 2011, 39:727-733.
8. Brait M, Sidransky D Cancer epigenetics: above and be-yond. Toxicol Mech Methods 2011, 21:275-288.
9. Eze OP, Starker LF, Carling T The role of epigenetic alterations in papillary thyroid carcinogenesis. J Thyroid Res 2011, 2011:895470.
10. Choi IS, Estecio MR, Nagano Y, Kimdo H, White JA, Yao JC, et al. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol 2007, 20:802-810.
11. Gonzalo V, Castellvi-Bel S, Balaguer F, Pellise M, Ocana T, Castells A Epigenetics of cancer. Gastroenterol Hepatol 2008, 31:37-45.
12. Oyama K, Kawakami K, Maeda K, Ishiguro K, Watanabe G The association between methylenetetrahydro-folate reductase polymorphism and promoter methylation in proximal colon cancer. Anticancer Res 2004, 24:649-654.
13. Batra V, Mishra KP Modulation of DNA methyltrans-ferase profile by methyl donor starvation followed by gamma irradiation. Mol Cell Biochem 2007, 294:181-187.
14. Zhu D, Hunter SB, Vertino PM, Van Meir EG Overex-pression of MBD2 in Glioblastoma Maintains Epigenetic Silencing and Inhibits the Antiangiogenic Function of the Tumor Suppressor Gene BAI1. Cancer Res 2011, 71:5859-5870.
15. Huang J, Vieira A DNA methylation, riboswitches, and transcription factor activity: fundamental mechanisms of gene-nutrient interactions involving vitamins. Mol Biol Rep 2006, 33:253-256.
16. Milutinovic S, D'Alessio AC, Detich N, Szyf M Val-proate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2007, 28:560-571.
17. Nicholson L, Singh GK, Osterwalder T, Roman GW, Davis RL, Keshishian H Spatial and temporal con-trol of gene expression in Drosophila using the inducible GeneSwitch GAL4 system. I. Screen for larval nervous system drivers. Genetics 2008, 178:215-234.
18. Chalitchagorn K, Shuangshoti S, Hourpai N, Kongrutta-nachok N, Tangkijvanich P, Thong-ngam D, Voravud N, et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 2004, 23:8841-8846.
19. Fraga MF, Agrelo R, Esteller M Cross-talk between aging and cancer: the epigenetic language. Ann N Y Acad Sci 2007, 1100:60-74.
20. Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Risch HA, Puopolo M, et al. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 2006, 12:1208-1214.
21. Elzagheid A, Kuopio T, Pyrhonen S, Collan Y Lymph node status as a guide to selection of available prognos-tic markers in breast cancer: the clinical practice of the future?. Diagn Pathol 2006, 1:41.
22. Murrell A, Ito Y, Verde G, Huddleston J, Woodfine K, Silengo MC, et al. Distinct methylation changes at the IGF2-H19 locus in congenital growth disorders and can-cer. PLoS One 2008, 3:e1849.
23. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, et al. Loss of IGF2 im-printing: a potential marker of colorectal cancer risk. Science 2003, 299:1753-1755.
24. Feil R, Charlton J, Bird AP, Walter J, Reik W Methylation analysis on individual chromosomes: improved pro-tocol for bisulphite genomic sequencing. Nucleic Acids Res 1994, 22:695-696.
25. Byun HM, Wong HL, Birnstein EA, Wolff EM, Liang G, Yang AS Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res 2007, 67:10753-10758.
26. Liu L, Li Y, Tollefsbol TO Gene-environment interactions and epigenetic basis of human diseases. Curr Issues Mol Biol 2008, 10:25-36.
27. Feinberg AP The epigenetics of cancer etiology. Semin Cancer Biol 2004, 14:427-432.
28. Zhang FF, Morabia A, Carroll J, Gonzalez K, Fulda K, Kaur M, et al. Dietary patterns are associated with levels of global genomic DNA methylation in a cancer-free population. J Nutr 2011, 141:1165-1171.
29. Friso S, Girelli D, Trabetti E, Olivieri O, Guarini P, Pig-natti PF, et al. The MTHFR 1298A>C polymorphism and genomic DNA methylation in human lymphocytes. Cancer Epidemiol Biomarkers Prev 2005, 14:938-943.
30. Cellarier E, Durando X, Vasson MP, Farges MC, Demi-den A, Maurizis JC, et al. Methionine dependency and cancer treatment. Cancer Treat Rev 2003, 29:489-499.
31. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R A second genetic polymorphism in methylenetetrahy-drofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998, 64:169-172.
32. Axume J, Smith SS, Pogribny IP, Moriarty DJ, Caudill MA The MTHFR 677TT genotype and folate intake interact to lower global leukocyte DNA methylation in young Mexican American women. Nutr Res 2007, 27:1317-1365.
33. Supic G, Jovic N, Kozomara R, Zeljic K, Magic Z In-teraction between the MTHFR C677T polymorphism and alcohol-impact on oral cancer risk and multiple DNA methylation of tumor-related genes. J Dent Res 2011, 90:65-70.
34. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorec-tal cancer. Cancer Res 1997, 57:1098-1102.
35. Yang CX, Matsuo K, Ito H, Shinoda M, Hatooka S, Hi-rose K, et al. Gene-environment interactions between alcohol drinking and the MTHFR C677T polymorphism impact on esophageal cancer risk: results of a case-con-trol study in Japan. Carcinogenesis 2005, 26:1285-1290.
36. Wang LD, Guo RF, Fan ZM, He X, Gao SS, Guo HQ, et al. Association of methylenetetrahydrofolate reductase and thymidylate synthase promoter polymorphisms with genetic susceptibility to esophageal and cardia cancer in a Chinese high-risk population. Dis Esophagus 2005, 18:177-184.